The Eldridge BBB-B CLO ETF (CLOZ) remains a recommended buy, providing an estimated 6.8% annual yield with monthly income distributions. It has shifted its portfolio towards higher-quality BBB CLOs to reduce risk, though it has underperformed peers year-to-date due to higher exposure to BB tranches. Despite this, its assets under management have grown, signaling renewed investor confidence following the recent Federal Reserve meeting. Key risks include potential rising CLO defaults, which could impact capital appreciation given CLOZ's larger BB tranche allocation compared to benchmarks and competitors.
Lexeo Therapeutics announced an educational event on October 21, 2026, focusing on clinical endpoints and outcome measures in PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM). The event will feature discussions by Lexeo's Chief Medical Officer and a lea...
EyePoint announced that its DURAVYU treatment for wet age-related macular degeneration (wet AMD) did not meet the primary goal of matching the visual improvement of the standard aflibercept treatment in the LUCIA Phase 3 trial. However, DURAVYU demon...
Marker Therapeutics has been awarded a $2.6 million grant from the FDA's Orphan Products Clinical Trials program to support a Phase 1 study of its MT-601 multi-antigen recognizing T cell therapy for locally advanced unresectable pancreatic cancer. Th...
Agility Robotics announced that Mark Vale, former UPS president and current CEO of Transportation Insight, will join its board and chair the audit committee after its merger with Churchill Capital Corp XI. Vale's extensive experience in global logist...
JazzCash, Pakistan's leading digital financial services platform, won the Silver Award in the Banking – InsurTech category at Money20/20 USA 2026 for its health-protection platform Sehat+. This platform provides affordable health insurance to Pakista...
